Recruitment to a large scale randomised controlled clinical trial in primary care: the Helicobacter Eradication Aspirin Trial (HEAT)
Recruitment to a large scale randomised controlled clinical trial in primary care: the Helicobacter Eradication Aspirin Trial (HEAT)
Background: The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter (H.) pylori eradication reduces hospitalisation for peptic ulcer bleeding. Recruited participants were aged 60 and over and taking aspirin (≤325 mg daily) for at least four months prior to consent. Based on results of a pilot study, a sample size calculation predicted 6600 H. pylori-positive randomised participants would be required, from 33,000 volunteers, recruited from 170,000 invited patients. Methodology was therefore designed for recruitment of large numbers of patients from primary care using a novel electronic search tool, automated mail-out and electronic follow-up. Recruitment started in 2012 and completed in 2017. Methods: All participants were recruited from GP practices, with assistance from the UK Clinical Research Network (UKCRN). H. pylori-positive participants were randomised to one week of eradication treatment or placebo. Recruitment was managed using a bespoke web-based database that communicated directly with a programmed search tool downloaded at participating practices. The primary endpoint is hospitalisation due to peptic ulcer bleeding. The trial will end when 87 adjudicated events have occurred, identified from searches of GP databases, review of secondary care admission data and mortality data, and reported events from randomised participants and GPs. Results: HEAT has recruited participants from 1208 GP practices across the UK. Of the 188,875 invitation letters sent, 38,771 returned expressions of interest. Of these, 30,166 patients were consented to the trial, of whom 5355 H. pylori-positive participants (17.8% of those consented) were randomised. Mean age at consent was 73.1 ± 6.9 (SD) years and 72.2% of participants were male. Of the randomised (H. pylori-positive) participants, 531 have died (as of 17 Sep 2020); none of the deaths was due to trial treatment. Conclusion: The HEAT trial methodology has demonstrated that recruitment of large numbers of patients from primary care is attainable, with the assistance of the UKCRN, and could be applied to other clinical outcomes studies. Trial registration: ClinicalTrials.gov; registration number NCT01506986. Registered on 10 Jan 2012.
Aspirin, Clinical research networks, Clinical trial, Demographics, H. pylori, Primary care, Recruitment, Ulcer bleeding
Stevenson, Diane J.
6acab417-432d-4d9f-88c8-ec3ab90f6c42
Avery, Anthony J.
ba667df1-c7e8-4812-855c-8f5d8c37ed86
Coupland, Carol
6efd69d5-8f84-45ac-9777-d4b07feeb2e2
Hobbs, F.D. Richard
9a0f0240-ff92-43ed-882a-2c3be3472559
Kendrick, Denise
33ad9db9-6d98-4e87-a2ad-323b289e3a16
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Morris, Clive
eccf88a9-1828-4390-ac36-258c2fec436e
Rubin, Greg P.
408cd38c-7cfc-49c2-8ca6-59df3fc29654
Smith, Murray D.
0a53a287-46bc-4a04-8d92-2da1d43475b5
Hawley, Christopher J.
266b205e-5063-42e1-b0ef-df334b0c4819
Dumbleton, Jennifer S.
0fc448d4-e5f2-4e92-aeb7-3443853e44c7
14 February 2022
Stevenson, Diane J.
6acab417-432d-4d9f-88c8-ec3ab90f6c42
Avery, Anthony J.
ba667df1-c7e8-4812-855c-8f5d8c37ed86
Coupland, Carol
6efd69d5-8f84-45ac-9777-d4b07feeb2e2
Hobbs, F.D. Richard
9a0f0240-ff92-43ed-882a-2c3be3472559
Kendrick, Denise
33ad9db9-6d98-4e87-a2ad-323b289e3a16
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Morris, Clive
eccf88a9-1828-4390-ac36-258c2fec436e
Rubin, Greg P.
408cd38c-7cfc-49c2-8ca6-59df3fc29654
Smith, Murray D.
0a53a287-46bc-4a04-8d92-2da1d43475b5
Hawley, Christopher J.
266b205e-5063-42e1-b0ef-df334b0c4819
Dumbleton, Jennifer S.
0fc448d4-e5f2-4e92-aeb7-3443853e44c7
Stevenson, Diane J., Avery, Anthony J., Coupland, Carol, Hobbs, F.D. Richard, Kendrick, Denise, Moore, Michael, Morris, Clive, Rubin, Greg P., Smith, Murray D., Hawley, Christopher J. and Dumbleton, Jennifer S.
(2022)
Recruitment to a large scale randomised controlled clinical trial in primary care: the Helicobacter Eradication Aspirin Trial (HEAT).
Trials, 23 (140), [140].
(doi:10.1186/s13063-022-06054-w).
Abstract
Background: The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter (H.) pylori eradication reduces hospitalisation for peptic ulcer bleeding. Recruited participants were aged 60 and over and taking aspirin (≤325 mg daily) for at least four months prior to consent. Based on results of a pilot study, a sample size calculation predicted 6600 H. pylori-positive randomised participants would be required, from 33,000 volunteers, recruited from 170,000 invited patients. Methodology was therefore designed for recruitment of large numbers of patients from primary care using a novel electronic search tool, automated mail-out and electronic follow-up. Recruitment started in 2012 and completed in 2017. Methods: All participants were recruited from GP practices, with assistance from the UK Clinical Research Network (UKCRN). H. pylori-positive participants were randomised to one week of eradication treatment or placebo. Recruitment was managed using a bespoke web-based database that communicated directly with a programmed search tool downloaded at participating practices. The primary endpoint is hospitalisation due to peptic ulcer bleeding. The trial will end when 87 adjudicated events have occurred, identified from searches of GP databases, review of secondary care admission data and mortality data, and reported events from randomised participants and GPs. Results: HEAT has recruited participants from 1208 GP practices across the UK. Of the 188,875 invitation letters sent, 38,771 returned expressions of interest. Of these, 30,166 patients were consented to the trial, of whom 5355 H. pylori-positive participants (17.8% of those consented) were randomised. Mean age at consent was 73.1 ± 6.9 (SD) years and 72.2% of participants were male. Of the randomised (H. pylori-positive) participants, 531 have died (as of 17 Sep 2020); none of the deaths was due to trial treatment. Conclusion: The HEAT trial methodology has demonstrated that recruitment of large numbers of patients from primary care is attainable, with the assistance of the UKCRN, and could be applied to other clinical outcomes studies. Trial registration: ClinicalTrials.gov; registration number NCT01506986. Registered on 10 Jan 2012.
Text
Demographics paper MAIN MANUSCRIPT
- Accepted Manuscript
Text
s13063-022-06054-w
- Version of Record
More information
Accepted/In Press date: 27 January 2022
Published date: 14 February 2022
Additional Information:
Funding Information:
We would like to thank the NIHR Health Technology Assessment Programme for their support for this trial, along with all participating CRNs, CCGs and GP practices, without whom this trial would not have been possible. We would also like to acknowledge and thank the help and support of TCR Nottingham Ltd, those involved in the pilot study, all the research nurses who worked on the trial, and the thousands of patients who volunteered.
Publisher Copyright:
© 2022, The Author(s).
Keywords:
Aspirin, Clinical research networks, Clinical trial, Demographics, H. pylori, Primary care, Recruitment, Ulcer bleeding
Identifiers
Local EPrints ID: 455131
URI: http://eprints.soton.ac.uk/id/eprint/455131
ISSN: 1745-6215
PURE UUID: 3678a20a-79d8-4924-acc3-fe09d21eea68
Catalogue record
Date deposited: 10 Mar 2022 17:51
Last modified: 15 Oct 2024 01:39
Export record
Altmetrics
Contributors
Author:
Diane J. Stevenson
Author:
Anthony J. Avery
Author:
Carol Coupland
Author:
F.D. Richard Hobbs
Author:
Denise Kendrick
Author:
Clive Morris
Author:
Greg P. Rubin
Author:
Murray D. Smith
Author:
Christopher J. Hawley
Author:
Jennifer S. Dumbleton
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics